+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy



Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy



Urology 74(1): 119-123



To study the clinical and bacteriologic picture of acute prostatitis caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli after transrectal ultrasound-guided prostate biopsy. The retrospective data from 1339 patients who had undergone transrectal ultrasound-guided biopsy from November 2003 to June 2008 were reviewed. An automatic biopsy gun with an 18-gauge needle was used to obtain 10-core biopsies for first biopsies and > or =12-core for repeat biopsies. These patients had received 500 mg ciprofloxacin orally twice daily for 5 days, beginning 24 hours before biopsy. All biopsies were performed as outpatient procedures. Of the 1339 patients, 28 (2.1%) had acute bacterial prostatitis detected after transrectal ultrasound-guided prostate biopsy. Acute prostatitis occurred after the first biopsy in 15 patients (1.3%) and after repeat biopsy in 13 (6.8%). The patients had developed infective symptoms a mean of 3 days after transrectal ultrasound-guided prostate biopsy. Of the 28 patients, 17 (61%) had positive urine and/or blood cultures, including E. coli in 14. Of the 14 patients, 6 had acute prostatitis caused by ESBL-producing E. coli. Bacteria isolated from urine were tested for drug susceptibility to a wide range of antibiotics. All patients with ESBL-producing E. coli were treated with imipenem. The bacteria detected in these urine cultures were resistant to ciprofloxacin, ceftriaxone, sulbactam/ampicillin, and cefazolin. Imipenem and piperacillin-tazobactam were the most active agents against ESBL-producing E. coli. ESBL-producing isolates had a significant reduction in activity for most antimicrobial agents, including fluoroquinolones and amikacin. The prompt initiation of effective antimicrobial treatment is essential in patients with ESBL-producing E. coli, and empirical decisions must be determined by knowledge of the local distribution of pathogens and their susceptibility.

(PDF emailed within 0-6 h: $19.90)

Accession: 053790135

Download citation: RISBibTeXText

PMID: 19464043

DOI: 10.1016/j.urology.2008.12.067


Related references

Impact of selective media for detecting fluoroquinolone-insusceptible/extended-spectrum beta-lactamase-producing Escherichia coli before transrectal prostate biopsy. International Journal of Urology 24(12): 842-847, 2017

Case of septic shock caused by extended spectrum β-lactamase producing Escherichia coli after transrectal prostate biopsy, successfully treated by endotoxin adsorption therapy. Hinyokika Kiyo. Acta Urologica Japonica 59(9): 593-596, 2014

Travel-associated extended-spectrum β-lactamase-producing Escherichia coli bloodstream infection following transrectal ultrasound-guided prostate biopsy. Bju International 109(7): E21-E22, 2012

Incidence and management of extended-spectrum beta-lactamase and quinolone-resistant Escherichia coli infections after prostate biopsy. Urology 84(5): 1001-1007, 2015

Pyomyositis caused by extended-spectrum beta-lactamase-producing Escherichia coli in a patient with acute myeloid leukemia. International Journal of Infectious Diseases 13(3): E85-E87, 2008

Chronic prostatitis caused by extended-spectrum β-lactamase-producing Escherichia coli managed using oral fosfomycin-A case report. Idcases 15: E00493, 2019

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clinical Microbiology and Infection 16(2): 132-136, 2010

High prevalence of extended-spectrum beta-lactamase-producing enterobacteriaceae in bacteremia after transrectal ultrasound-guided prostate biopsy: a need for changing preventive protocol. Urology 74(6): 1195-1199, 2010

Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Archives of Internal Medicine 168(17): 1897-1902, 2008

Positive culture for extended-spectrum β-lactamase during acute prostatitis after prostate biopsy is a risk factor for progression to chronic prostatitis. Urology 81(6): 1209-1212, 2013

Therapeutic options for bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clinical Infectious Diseases 51(1): 119-20; Author Reply 120-1, 2010

Incidence of extended spectrum beta lactamase producing Escherichia coli among patients, healthy individuals and in the environment. Indian Journal of Medical Microbiology 32(2): 172-174, 2014

Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Journal of Clinical Microbiology 46(2): 817-820, 2007

Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 68(6): 1169-1174, 2006

Mycotic aneurysm of the thoracic aorta caused by extended-spectrum beta-lactamase-producing Escherichia coli. Interactive Cardiovascular and Thoracic Surgery 12(1): 61-62, 2011